{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,2]],"date-time":"2025-09-02T10:35:17Z","timestamp":1756809317763,"version":"3.41.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2001,1]]},"DOI":"10.1023\/a:1011198432013","type":"journal-article","created":{"date-parts":[[2002,12,23]],"date-time":"2002-12-23T08:43:03Z","timestamp":1040632983000},"page":"11-13","source":"Crossref","is-referenced-by-count":7,"title":["New Treasures from Old? EPHESUS"],"prefix":"10.1007","volume":"15","author":[{"given":"Marc A.","family":"Pfeffer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"336293_CR1","first-page":"67","volume-title":"Textbook of Interventional Cardiology","author":"MA. Pfeffer","year":"1999","unstructured":"Pfeffer MA. Angiotensin converting enzyme inhibition. In: Topol EJ, ed. Textbook of Interventional Cardiology, 3rd ed. Philadelphia: W.B. Saunders Company, 1999; 67-77.","edition":"3rd ed."},{"key":"336293_CR2","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","volume":"329","author":"EJ Lewis","year":"1993","unstructured":"Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy: The Collaborative Study Group. NEngl J Med 1993; 329: 1456-1462.","journal-title":"NEngl J Med"},{"key":"336293_CR3","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/euhj.1999.1547","volume":"20","author":"R Willenheimer","year":"1999","unstructured":"Willenheimer R, Dahlof B, Rydberg E, Erhardt L. AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions. Europ Heart J 1999; 20: 997-1008.","journal-title":"Europ Heart J"},{"key":"336293_CR4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1067\/mhj.2000.108832","volume":"140","author":"MA Pfeffer","year":"2000","unstructured":"Pfeffer MA, McMurray J, Leizorovicz A, et al. for the VALIANT Investigators. Valsartan in Acute Myocardial Infarction Trial (VALIANT): rationale and design. Am Heart J 2000; 140: 727-734.","journal-title":"Am Heart J"},{"key":"336293_CR5","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S1071-9164(99)90013-1","volume":"5","author":"K Swedberg","year":"1999","unstructured":"Swedberg K, Pfeffer M, Granger C, et al. for the CHARM-Programme Investigators. Candesartan in heart failure-assessment of reduction in mortality and morbidity (CHARM): rationale and design. J Card Failure 1999; 5: 276-282.","journal-title":"J Card Failure"},{"key":"336293_CR6","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0002-9149(98)00898-4","volume":"83","author":"K Dickstein","year":"1999","unstructured":"Dickstein K, Kjekshus J. Comparison of the effects of losartan and captopril on mortality in patients after acute myocardial infarction: The OPTIMAAL Trial Design. Am J Cardiol 1999; 83: 477-481.","journal-title":"Am J Cardiol"},{"key":"336293_CR7","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1161\/01.CIR.83.6.1849","volume":"83","author":"KT Weber","year":"1991","unstructured":"Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83: 1849-1865.","journal-title":"Circulation"},{"issue":"Suppl1","key":"336293_CR8","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1097\/00005344-199212001-00010","volume":"20","author":"KT Weber","year":"1992","unstructured":"Weber KT, Brilla CG. Myocardial fibrosis and the renin-angiotensin-aldosterone system. J Cardiovasc Pharmacol 1992; 20(Suppl 1): S48-S54.","journal-title":"J Cardiovasc Pharmacol"},{"key":"336293_CR9","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1016\/S0022-2828(95)90359-3","volume":"27","author":"SE Campbell","year":"1995","unstructured":"Campbell SE, Janicki JS, Weber KT. Temporal differences in fibroblast proliferation and phenotype expression in response to chronic administration of angiotensin II or aldosterone. J Mol Cell Cardiol 1995; 27: 1545-1560.","journal-title":"J Mol Cell Cardiol"},{"key":"336293_CR10","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1053\/euhj.1998.1099","volume":"19","author":"DA Duprez","year":"1998","unstructured":"Duprez DA, De Buyzere ML, Rietzschel ER, et al. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients. Eur Heart J 1998; 19: 1371-1376.","journal-title":"Eur Heart J"},{"key":"336293_CR11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1161\/01.HYP.24.5.571","volume":"24","author":"W. Wang","year":"1994","unstructured":"Wang W. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog. Hypertension 1994; 24: 571-575.","journal-title":"Hypertension"},{"key":"336293_CR12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1046\/j.1365-2125.1999.00954.x","volume":"47","author":"AD. Struthers","year":"1999","unstructured":"Struthers AD. Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure? Br J Clin Pharmacol 1999; 47: 479-482.","journal-title":"Br J Clin Pharmacol"},{"key":"336293_CR13","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/S0002-9149(96)00465-1","volume":"78","author":"The RALES Investigators.","year":"1996","unstructured":"The RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the randomized aldactone evaluation study [RALES]). Am J Cardiol 1996; 78: 902-912.","journal-title":"Am J Cardiol"},{"key":"336293_CR14","unstructured":"Pitt B, Williams G, Remme W, et al. The EPHESUStrial: eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction (Eplerenone's neuroHormonal Efficacy and Survival Study). Cardiovasc Drugs Therap 2000; in press."},{"key":"336293_CR15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/384353a0","volume":"384","author":"S Sakai","year":"1996","unstructured":"Sakai S, Miyauchi T, Kobayashi M, Yamaguchi I, Goto K, Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 1996; 384: 353-355.","journal-title":"Nature"},{"key":"336293_CR16","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S0008-6363(98)00159-X","volume":"39","author":"P Mulder","year":"1998","unstructured":"Mulder P, Richard V, Bouchart F, Derumeaux G, Munter K, Thuillez C. Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure. Cardiovasc Res 1998; 39: 600-608.","journal-title":"Cardiovasc Res"},{"key":"336293_CR17","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1161\/01.CIR.98.21.2323","volume":"98","author":"QT Nguyen","year":"1998","unstructured":"Nguyen QT, Cernacek P, Calderoni A, et al. Rouleau JL.Endothelin A receptor blockade causes adverse left ventricular remodeling but improves pulmonary artery pressure after infarction in the rat. Circulation 1998; 98: 2323-2330.","journal-title":"Circulation"},{"key":"336293_CR18","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1023\/A:1007890126061","volume":"14","author":"JM Pfeffer","year":"2000","unstructured":"Pfeffer JM, Finn PV, Zornoff LAM, Pfeffer MA. Endothelin-Areceptor antagonism during acute myocardial infarction in rats. Cardiovasc Drugs Therap 2000; 14: 577-585.","journal-title":"Cardiovasc Drugs Therap"},{"key":"336293_CR19","unstructured":"The effect of eplerenone on wound healing, ventricular remodeling, and infarct expansion following myocardial infarction. G.D. Searle & Co., Document No. BRD99D 1973; Report in preparation (as cited in reference 14 The EPHESUS Trial: Eplerenone in patients with heart failure due to systolic dysfunction complicating acute myocardial infarction. Cardiovasc Drugs Therap 2000; in press)."},{"key":"336293_CR20","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1067\/mhj.2001.111258","volume":"141","author":"MG Modena","year":"2001","unstructured":"Modena MG, Aveta P, Menozzi A, Rossi R. Aldosterone inhibition limits collagen synthesis and progressive left ventricular enlargement after anterior myocardial infarction. Am Heart J 2001; 141: 41-46.","journal-title":"Am Heart J"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1011198432013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1011198432013\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1011198432013.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T19:21:15Z","timestamp":1751052075000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1011198432013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["336293"],"URL":"https:\/\/doi.org\/10.1023\/a:1011198432013","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"type":"print","value":"0920-3206"},{"type":"electronic","value":"1573-7241"}],"subject":[],"published":{"date-parts":[[2001,1]]}}}